Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros
Ditte M Karpf
Flemming S Nielsen
Anette Mullertz

Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark; ^1Contributed equally to this work

Abstract: This work is an attempt to give an overview of the clinical data available on lipid based formulations. Lipid and surfactant based formulations are recognized as a feasible approach to improve bioavailability of poorly soluble compounds. However not many clinical studies have been published so far. Several drug products intended for oral administration have been marketed utilizing lipid and surfactant based formulations. Sandimmune® and Sandimmune Neoral® (cyclosporin A, Novartis), Norvir® (ritonavir), and Fortovase® (saquinavir) have been formulated in self-emulsifying drug delivery systems (SEDDS). This review summarizes published pharmacokinetic studies of orally administered lipid based formulations of poorly aqueous soluble drugs in human subjects. Special attention has been paid to the physicochemical characteristics of the formulations, when available and the impact of these properties on the in vivo performance of the formulation. Equally important is the effect of concurrent food intake on the bioavailability of poorly soluble compounds. The effect of food on the bioavailability of compounds formulated in lipid and surfactant based formulations is also reviewed.

Keywords: lipid formulations, poorly soluble compounds, pharmacokinetics, human clinical studies, lipophilic compounds, SEDDS, emulsions, food effect

Introduction
The purpose of this article is to review the clinical trials on lipid and surfactant based formulations of poorly soluble compounds for oral administration. Despite a plethora of articles dealing with orally administered lipid based formulations of poorly soluble compounds, the majority of these articles emphasize issues related to pharmacology and toxicity rather than formulation issues. Therefore special attention has been paid to the differences in the pharmacokinetics upon oral administration of different lipid formulations.

The use of lipid and surfactant based formulations is one of several approaches that has been applied in order to improve the oral bioavailability of poorly aqueous soluble compounds intended for oral administration. The approach has proved efficient and hence has received attention, especially in academia. Lipid and surfactant based systems are physically very different systems including systems like emulsions, microemulsion, self-emulsifying drug delivery systems (SEDDS), micellar solutions, and dry emulsions like lipid solutions and lipid suspensions.

The number of excipients which are pharmaceutically acceptable and applicable in the formulation of lipid and surfactant based systems is large. The use of solubilizing excipients in marketed formulations of poorly soluble compounds has been reviewed recently (Strickley 2004).

The bioavailability enhancing properties of lipid and surfactant based systems has most often been attributed to the ability of the vehicles to keep the compound in solution in the gastrointestinal (GI) tract and thereby maintaining a maximal free drug concentration (Porter and Charman 2001). However the underlying mechanisms of
absorption from lipid and surfactant based systems is not fully understood.

The majority of the knowledge of the in vivo performance and suggested mechanism of drug absorption from lipid based formulations originates from studies in animals. Several authors have attempted to identify and describe the important parameters in order to set-up rational strategies for development of new lipid based formulations. The parameters that have been emphasized so far are the degree of emulsification (in terms of particle size), and the solubility of the drug both in the digested and nondigested formulation of the resultant dispersion (Humberstone and Charman 1997; Pouton 2000; Porter and Charman 2001; Porter et al 2004; Nielsen et al 2007).

Furthermore a number of typically employed excipients are susceptible to enzymatic degradation in the GI tract. Excipients susceptible to degradation include natural di- and triglycerides as well as some commonly used surfactants like Labrasol, Labrafil, Gelucire, Cremophor, Tween 80 (Khosravani et al 2002, Seebaluck et al 2004, Larsen et al 2006).

The release of compound from SEDDS based formulation is thought to take place by two major pathways: Interfacial transfer and degradation of vehicle (de Smidt et al 2004; Porter et al 2004). Interfacial transfer can be described as a concentration gradient driven process in which the compound diffuses from the formulation into the bulk or directly over the intestinal membrane. The rate and extent of interfacial transfer is thought to be governed by partition coefficient and solubility in the donor (formulation) and recipient phase particle size and hence surface area of formulation (Armstrong and James 1980). The second pathway is degradation of the vehicle inducing the release of the compound out of the vehicle. As mentioned above, for lipid based formulations, the most important degradation is the lipolysis catalyzed by pancreatic lipase. The release rate is thought to be dependent on the solubility of the compound in the formulation and rate and extent of the degradation of the vehicle. Lipolysis of triacylglycerols (TG) by the pancreatic lipase–colipase complex releases monoacylglycerols, diacylglycerols and free fatty acids. These lipolysis products are amphiphiles that will further assist the solubilization of poorly soluble compounds in the GI fluids.

Recently it has been demonstrated that a number of excipients should be considered as more than just inert substances. It has been shown that Cremophor EL, Tween 80, Labrasol, Miglyol polyethoxylated, can inhibit the PGP efflux transporter (p-glycoprotein) (Hugger et al 2002; Shono et al 2004; Cornaire et al 2004) and hereby potentially improve bioavailability of drug molecules being PGP substrates. A number of excipients have shown to influence the lymphatic transport both in rats, and have an impact to the chylomicron secretion in caco-2 cells, which is also believed to be an indicator of lymphatic transport (Rege et al 2002; Seeballuck et al 2003; Karpf et al 2004).

These advances in the characterization of the mechanisms underlying the bioavailability enhancing properties of lipid and surfactant based formulations mark a change in formulation strategy away from the more empirically based formulation testing to a more rational formulation strategy. However it also implies that more work is needed in the field and that a battery of different methods should be used to describe the different mechanisms.

Among the lipid based formulations used for oral delivery, SEDDS and self-microemulsifying drug delivery systems (SMEDDS) have been characterized more systematically from a physicochemical point of view. They are isotropic mixtures of oil (pure triglyceride oils, mixed glycerides), surfactant (hydrophilic or/and lipophilic), water soluble co-solvents and the poorly soluble compound. Development and characterization of SEDDS and SMEDDS has been extensively reviewed (Pouton 1997; Gershank and Benita 2000; Gursoy and Benita 2004; Pouton 2006). A number of biophysical techniques have been used to characterize these systems (Lawrence and Rees 2000). Scattering techniques such as dynamic light scattering (DLS) (Constantinides and Scarlet 1997), small angle neutron scattering (SANS) (Bergenholtz et al 1995) and small angle x-ray scattering (SAXS) (Regev et al 1996) can offer useful information for the structure of the microemulsions together with freeze fracture electron microscopy (Vinson et al 1991). Dielectric viscosity, and conductivity measurements can offer new insights on the characterization of these systems on a macroscopic level (Acosta et al 1996).

Equally important are the interactions between drugs and food. The impact of food on the bioavailability of drugs in clinical studies has recently been reviewed by Schmidt and Dalhoff (2002). Food delays the gastric emptying rate and induces secretion of bile and pancreatic juices, while the passage time of the small intestine remains virtually unchanged. Hence food intake can increase the solubilization time and increase the solubility of a poorly soluble drug, which will affect the pharmacokinetic parameters.

In the following, data from clinical studies of oral lipid based formulations of poorly soluble compounds performed are presented. Table 1 summarizes the type of study and the formulations used.
| Compound       | Study design                                  | Formulation composition | Formulation characteristics                                                                 | Comments                                                                                      | Authors      | Year  |
|----------------|-----------------------------------------------|-------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------|-------|
| Atovaquone     | Randomized balanced three-way crossover design (n = 9) | Tablets: Aqueous suspension An oil suspension | Oil suspension consisted of miglyol (fractionated coconut oil) | AUC: Oil suspension > aqueous suspension > tablets C\textsubscript{max}: Oil suspension > aqueous suspension > tablets | Rolan et al | 1994  |
| Clomethiazole  | Cross-over study (n = 10)                     | Tablets: Lipid mixture Aqueous mixture | Lipid mixture contained increasing amounts of arachis oil Aqueous suspension contain the corresponded acid form | Plasma concentrations: Aqueous suspension > lipid mixture > tablets. A doubling in the dosed arachis oil resulted in higher plasma concentrations. | Fischler et al | 1973  |
| Cyclosporine   | 12 fasted healthy volunteers, four way cross-over | Neoral\textsuperscript{1} | 150 mg CsA from either Sandimmune or B, C or D. B: Microemulsion with fast in vitro release. C: Solid micellar solution with fast in vitro release. D: Microemulsion with slow in vitro release. | AUC: B > C > D > Sandimmune \text{C}\textsubscript{max}: B > C > D > Sandimmune \text{T}\textsubscript{max}: B < C < D < Sandimmune | Drewe et al | 1992  |
|                |                                               | Neoral \textsuperscript{2} | 24 fasted healthy volunteers, three way cross-over | T\textsubscript{lag}: Mixed with juice < Mixed with water < Soft gelatine capsule. All other PK parameters equal. | Kovarik et al | 1993  |
|                |                                               | Neoral and Sandimmune   | 24 fasted healthy volunteers, two way cross-over with replication | AUC: Neoral > Sandimmune \text{C}\textsubscript{max}: Neoral > Sandimmune \text{T}\textsubscript{max}: Neoral < Sandimmune \text{T}\textsubscript{1/2}: Neoral < Sandimmune Neoral exhibit lower Intrasubject and intersubject variability (%CV) than Sandimmune. | Kovarik et al | 1994  |
|                |                                               | Neoral and Sandimmune   | 24 healthy volunteers, four way cross-over, fasted or with a fat-rich meal | Fasted AUC: Neoral > Sandimmune. Fed AUC: Sandimmune > Neoral. Fasted \text{C}\textsubscript{max}: Neoral > Sandimmune. Fed \text{C}\textsubscript{max}: Neoral > Sandimmune. Fasted and fed \text{T}\textsubscript{max}: Neoral < Sandimmune | Mueller et al | 1994b |

(Continued)
| Compound                | Study design                          | Formulation composition | Formulation characteristics | Comments                                                                 | Authors               | Year  |
|-------------------------|---------------------------------------|-------------------------|-----------------------------|--------------------------------------------------------------------------|-----------------------|-------|
| 48 fasted healthy      | Neoral and Sandimmune                 | 200 mg to 800 mg CsA    | Neoral exhibit linear bio availability in the dose range 200 – 800 mg but Sandimmune did not. AUC: Neoral 174% to 239% higher than Sandimmune. | Mueller et al         | 1994a |       |
| volunteers, two parallel study groups, four way cross-over | as Neoral or Sandimmune               |                         |                             |                                                                          |                       |       |
| 23 healthy volunteers  | Neoral and Sandimmune                 | 7.5 mg/kg CsA from Neoral and Sandimmune | AUC: Neoral ~ Sandimmune C<sub>max</sub>: Neoral > Sandimmune | González-Llaven et al | 1999  |       |
| fed a fat-rich breakfast |                                       |                         |                             |                                                                          |                       |       |
| 30 minutes prior dosing, two-way cross-over |                                       |                         |                             |                                                                          |                       |       |
| 24 healthy volunteers  | SMEDDS and non-SMEDDS capsules Lipospheres, | 200 mg single oral dose of each treatment 200 mg of cyclosporin, lipospheres containing Tween 80, Span 80, Chremophor RH 40, phospholipids, Tricarpin, Size from 25–400 nm | AUC SMEDDS > AUC non-SMEDDS Higher AUC and C<sub>max</sub> with lipospheres with small diameter | Postolache et al      | 2002  |       |
| open randomized        |                                       |                         |                             |                                                                          | Bekerman et al        | 2004  |       |
| 6 healthy volunteers   |                                       |                         |                             |                                                                          |                       |       |
| Fasted healthy volunteers (three in prediction study and six in confirmatory study), open cross-over study | Galactolipid SEDDS (G-SEDDS) and Neoral | 300 mg CsA from Galactolipid SEDDS and Neoral, Galactolipid SEDDS particle size of 16–20 µm (volume median diameter) | AUC: Neoral > G-SEDDS C<sub>max</sub>: Neoral ~ G-SEDDS T<sub>max</sub>: Neoral ~ G-SEDDS | Odeberg et al        | 2003  |       |
| Danazol (logP = 4.53)<sup>a</sup> | Randomized crossover fed/fasted study (n = 11 females) | Danocrine capsule O/w-emulsion | Emulsion contained glycerol mono-oleate and was physical stable for 6 months. | AUC: Capsule<sub>fasted</sub> > Capsule<sub>fed</sub> Emulsion<sub>fasted</sub> ~ emulsion<sub>fed</sub> | Charman et al        | 1993  |       |
| Diazepam (logP = 2.84)<sup>a</sup> | Crossover, 2 weeks washout (n = 4), fasted | Tablets Lipid solution | Lipid solution contained MCT | No significant difference in plasma diazepam levels between tablets or lipid solution. However lipid solution was less variable. | Yamahira et al        | 1979  |       |
| Dicumarol (logP of 3.66)<sup>a</sup> | Human (n = 4), fasted | Redispersed freeze-dried drug-milk/liquid, | Capsules containing 300 mg drug particles (49 µm) and 200 ml milk | Statistically significant differences were found between area under the curve, maximum plasma concentration with dicumarol-milk formulation. | Macheras et al (a)   | 1986  |       |
| Flufenamic acid (logP = 3.98)<sup>a</sup> | Random design 15 days washout (n = 9) | IR dosage form Lipid mixture | Lipid mixture contained vegetable oil hydrogenated vegetable oil, beeswax and soy lecithin | Mean plasma concentrations: Lipid mixture > IR dosage form at 90 min | Angellucci et al      | 1976  |       |
| Griseofulvin (logP 0.68)<sup>a</sup> | Random crossover (n = 5) | Lipid mixture Aqueous suspension Tablets | Lipid mixture contained corn-oil in water emulsions with dispersed drug | Bioavailability determined via urinary excretion: Lipid mixture > tablets ~ aqueous suspension. Absorption increased with increasing lipid amounts and reached plateau with 6 g of lipid Bioavailability determined via urinary excretion: o/w-emulsion ~ tablets Absorption was significantly decreased upon 2 g corn oil in the o/w-emulsion compared with the higher lipid amounts. | Bates et al           | 1975  |       |
| Four-way crossover study (latin square design) (n = 4) | O/w-emulsion Tablets | O/w-emulsion contained 2, 4.6 or 12 g of corn oil |                                                                      |                                                                          | Bates et al           | 1977  |       |
| Drug                          | Species | Lipid matrix | Capsule formulation | LXS (lymph-X-Sorb™) is an organized lipid matrix that consists of lyso-PC, MG and FA | Equivalent peak plasma concentrations were obtained using LXS at 20% of the capsular compound amount. | http://www.avantilipids.com/LXS-DD.asp |
|-------------------------------|---------|--------------|---------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------|
| 4-Hydroxyphenyl retinamide   | Humans  | Lipid matrix (LXS) | Capsule formulation |                                                                                   |                                                                                                      |                                      |
| (Fenretinide)                 |         |              |                     |                                                                                   |                                                                                                      |                                      |
| (Log P 5.50)                  |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Nitrofurantoin                | Human n = 4 fasted | Redispersed freeze-dried drug powder | Capsule containing 100 mg drug particles (75 µm) and 200 or 400 ml milk |                                                                                   | Urine data revealed superiority of the nitrofurantoin-milk formulations regenereated with 200 and 400 mL of milk over the corresponding capsule |                                      |
| (Log P not computable)        |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Paclitaxel                    | Randomized design, 2 weeks washout (n = 6) | Cremophor EL solution Polysorbate 80 solution | Both solutions contained ethanol. Prior to administration, all patients received cyclosporine to inhibit the P-gp efflux transporter. |                                                                                   |                                                                                                      |                                      |
| (Log P not computable)        |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Progesterone                  | 3 days washout (n = 7) | Plain-milled IR Micronized IR Plain-milled in LCT | LCT was a mixture of natural oils that were high in long-chained unsaturated FA |                                                                                   |                                                                                                      |                                      |
| (Log P 3.78)                  |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Quingestrone                  | I week washout (n = 1, each administration repeated 1–4 times) Fed/fasted | Oil suspension Oil solution powder | Oil suspension in sesame oil (10 µm particle size) Oil solution in sesame oil |                                                                                   | Bioavailability estimated by urinary excretion (fasted state): oil solution > oil suspension > powder. Fed state increased bioavailability | Bruni et al 1970 |
| (Log P 4.91)                  |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Q10 (Ubiquinone)              | Four way randomized cross-over (n = 10) | Oil solution Oil and Tween Oil, Tween and lecithin | Oil was soybean oil. Different amounts of oil and surfactants were administered. |                                                                                   |                                                                                                      |                                      |
| (Log P not computable)        |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Retinyl palmitate             | I-year, randomized, double blind controlled trial (n = 78 with cystic fibrosis) | Organized lipid matrix (OLM) TG-based nutritional supplement | OLM has a melting point of 64.6 °C, CMC = 0.1 mM and consists of Lym-X-Sorb (lyso-PC, MG, FA in 1:4:2) |                                                                                   | AUC: OLM > TG-based nutritional supplement in cystic fibrosis patients | Lepage et al 2002 |
| (Log P 11.0)                  |         |              |                     |                                                                                   |                                                                                                      |                                      |
| Saquinavir                    | Randomized, placebo-controlled, double-blind, four phase cross-over. 1 week washout (n = 8) | Invirase® with 0, 100, 1000 or 5000 mg Cremophor | Fortovase® contain medium chain MG and DG |                                                                                   |                                                                                                      |                                      |
| (Log P 2.73)                  |         |              |                     |                                                                                   |                                                                                                      |                                      |
|                              | Open-label, randomized, 2 x 2 crossover study (n = 24) HIV-patients HIV-patients n = 13 | Fortovase® Invirase® co-dosed with ritonavir Fortovase® Invirase® co-dosed with ritanavir | Fortovase® contain medium chain MG and DG |                                                                                   |                                                                                                      |                                      |
|                              |         |              |                     |                                                                                   |                                                                                                      |                                      |
|                              |         |              |                     |                                                                                   |                                                                                                      |                                      |
|                              |         |              |                     |                                                                                   |                                                                                                      |                                      |

(Continued)
For practical reasons the studies presented in the current work have been categorized based on the physicochemical characteristics (oil, suspensions, emulsions, SEDDS, and surfactant based systems). Furthermore the studies on the effect of food to oral bioavailability in humans have been reviewed.

**Oil solutions**

Lipid based formulations can enhance the bioavailability of poorly soluble drug substances by keeping the compound in solution. Medium chain triacylglycerides (MCT) and long chain triacylglycerides (LCT) are commonly used for the lipid based formulations. Several major differences exist between MCT and LCT in respect with their in vivo fate, such as lipolytic products, differences in the modulation on gastric emptying (Hunt and Knox 1968) and the contraction of the gallbladder in humans (Ladas et al 1984). Long chain lipolytic products delay gastric emptying and facilitate the contraction of the gallbladder to a larger extent than the medium chain lipolytic products (Hunt and Knox 1968).

The bioavailability of quingestrone (progesterone 3-cyclopentyl enol ether belonging to the enol ethers of Δ¹-kerosteroids) after oral administration to human subjects was evaluated by measuring the urinary excretion of pregnanediol and allopregnanediols (Bruni and Galleti 1970). 100 mg of the compound prepared either as micronized powder (with particle size less than 10 µm), an oil suspension in 0.3 ml of sesame oil (with particle size less than 10 µm), or an oil solution in 2.5 ml of sesame oil. Bioavailability of quingestrone was determined as the total urinary secretion for both metabolites. The urinary excretion was highest when the oil solution (6.43 ± 0.18 mg was administered compared with the oil suspension (2.96 ± 0.27 mg) or and the micronized powder (0.91 ± 0.02 mg).

The relative bioavailability of clomethiazole (base form) was investigated after oral administration of two arachis oil formulation both in capsules and a tablet formulation to fasting healthy volunteers (Fischler et al 1973). Higher plasma concentrations were obtained from the oil filled capsules and the absorption was more rapid, compared with tablets. The two arachis oil formulations consisted of clomethiazole and arachis oil 1:1 (384 mg + 384 mg) or 1:2 (384 mg + 768 mg) on a weight basis, respectively. Increasing the arachis oil to clomethiazole ratio from 1:1 to 2:1 resulted in a 1.5 times increase in C_{max}, suggesting an increase in bioavailability with increase of co-administered oil amount. Doubling the clomethiazole dose, but keeping the oil: drug ratio at 1:1 resulted in a 1.7 times increase
compared with a tablet formulation indicating nonlinear absorption kinetics. The results emphasizing the impact of the solubilization capacity of the lipid vehicle to the overall performance of the formulation

A soft capsule contained 200 mg of flufenamic acid (an analgesic anti-inflammatory agent), 100 mg of vegetable oil, 40 mg of hydrogenated vegetable oil, 8 mg of beeswax and 5 mg of soya lecithin and a hard gelatin capsules contained 200 mg flufenamic acid and 20 mg of magnesium stearate were orally administered to healthy volunteers (Angelluci et al 1976). The plasma levels more than doubled 90 minutes after administration of the lipid solution compared with the powder formulation. However after 180 and 360 minutes the plasma levels were lower after administration of the soft capsules. Due to the low number of plasma samples, it as not possible to identify any significant differences. The different plasma curves observed for the two pharmaceuticals forms can be attributed to physicochemical factors, triggered by excipients present in the soft gelatin capsule which result in a faster absorption of the drug.

The absorption of diazepam (benzodiazepine derivative) in fasted human subjects when dosing 5 mg in either a medium chain triglyceride formulation (2% diazepam-MCT solution) or a commercially available tablet formulation (Serenzin®, Sumitomo Chemical Co) in a crossover study was investigated by Yamahira and colleagues (1979). There was no significant difference in the average plasma profiles arising from the two formulations. The authors mainly attributed this to the large intersubject variation and the limited number of subjects (n = 4) enrolled in the study. However upon repeated administrations, the MCT solution showed less intrasubject variation. The authors suggested that MCT solution of diazepam produced a more uniform drug absorption rate compared with the tablets for individual patients.

The impact of the physical characteristics of a formulation has been demonstrated by Hargrove and colleagues (1989) in a clinical study with progesterone. Progesterone is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women. Four different preparations were made: plain milled progesterone, micronized progesterone, plain-milled progesterone in oil, micronized progesterone in oil. Suspending the micronized progesterone in oil more than doubled the \( C_{\text{max}} \), compared with micronized powder, while there was no effect of suspending the nonmicronized progesterone in oil. These results emphasize the effect of concomitant lipid digestion in dissolution of drug, at the same time also showing that the particle size of the solid drug is important.

The effect of medium chain triglyceride was studied by Rolan et al in 1994. In this approach, absorption of 500 mg atovaquone (an antiprotozoal agent) from either a suspension in 30 ml of Miglyol (fractionated coconut oil, medium chain triglyceride), an aqueous suspension using 0.25% w/v methylcellulose as suspending agent, or two 250 mg tablets of atovaquone were used. The AUC values were at the same levels for the aqueous and oil suspensions (144 ± 48 µg/ml·hr and 144 ± 124 µg/ml·hr respectively), the \( C_{\text{max}} \) increased for both formulations (2.7 ± 1.1 µg/ml for the aqueous suspension and 2.0 ± 1.8 µg/ml for the oil) compared with the tablets (1.1 ± 0.6 µg/ml). The higher absorption of atovaquone from the aqueous and oil suspensions compared with tablets was attributed to a better dispersion, allowing a faster solubilization of the drug.

Two oil solutions containing long chain and medium chain triglycerides with vitamin D were administered in human volunteers (Holmberg et al 1990). Higher AUC values obtained for the LCT solution (peanut oil) compared with the MCT solution (Miglyol 812) suggesting that the presence of long chain fatty acids enhance the absorption of vitamin D.

In four out of seven studies the presence of long chain triglycerides (LCT) significantly increased the oral absorption of the drugs (Bruni and Galleti 1970; Fischler et al 1973; Hargrove et al 1989; Holmberg et al 1990). Furthermore LCT formulations demonstrated higher oral absorption compared with MCT ones (Holmberg et al 1990). In contrast no significant difference in the absorption observed among oil formulations containing medium chain triglycerides MCT and tablets (Yamahira et al 1979; Rolan et al in 1994). Finally in one case the presence of LCT solutions didn’t enhance the absorption of the drug compared with the tablets (Angelluci et al 1976). Despite the fact that the results seem to be case specific, there are indications that LCT oil solutions perform better compared with MCT solutions. However it is rather difficult to draw conclusions because of the limited number of studies and the fact that there are no clear indications of which characteristics of a compound that are determining whether LCT or MCT oils give better bioavailability.

**Emulsions**

Another approach to increase the bioavailability of poorly water solute drugs is to formulate them in lipid emulsions.

Bioavailability studies in humans were carried out using o/w-emulsions, aqueous suspensions and commercial tablets (Bates and Sequeira 1975) of griseofulvin which is an antifungal antibiotic and it is commonly used in the treatment of dermatophyte infections in humans. Four dosage
forms containing micronized griseofulvin were evaluated by administration to humans. The corn o/w emulsion and aqueous suspension both contained 300 mg of polysorbate 60 in emulsion and 500 mg of suspended griseofulvin per 30 g of formulation. Two different commercial tablets contained 500 mg of micronized griseofulvin. The four dosage forms were administered in a random cross-over fashion to five fasting subjects in the form of 30 g of the corn oil emulsion, 30 g aqueous suspension and the tablets and the drug absorption was monitored from urinary excretion data for the major metabolite (6-desmethylgriseofulvin). Administration of o/w emulsion resulted in a 3–4 fold increase approximately, in the maximum excretion rate (mg/hr) of total 6-desmethylgriseofulvin. The bioavailability from the o/w emulsion increased 2 times compared with the other dosage forms. Such behavior attributed to the presence of linoleic acid contained in the lipolysis products which may inhibit the GI motility and stimulate the gallbladder evacuation.

In a follow up study the effect of different amounts of lipid emulsion was investigated (Bates et al 1977). However the total 6-desmethylgriseofulvin excretion rate profiles were quite similar after administration of the ultramicrosize griseofulvin tablets and 5, 10, 15, and 30 g of o/w emulsion used in the that study.

Lipid and surfactant based systems have been used for coenzyme Q10 (ubiquinone) which is a lipid soluble antioxidant, suggested to have a positive influence in congestive cardiac failure. The absorption of coenzyme Q10 was followed upon administration in different lipid dosage forms (Weis et al 1994). The tested formulations included 100 mg coenzyme Q10 i) suspended in soy bean oil (400 mg) administered in a soft gelatine capsule ii) in a mixture of polysorbate 80 (20 mg), phoshatidylcholine (100 mg) and soybean oil (280 mg) and iii) in a mixture of polysorbate 80 (20 mg) and soy bean oil (380 mg). The suspension in pure soy bean oil increased the bioavailability of coenzyme Q10 significantly compared with the lipid mixtures that included surfactant systems. It was suggested, that possibly the formation of mixed micelles containing polysorbate 80 phosphatidylcholine and soyabean oil for formulation ii) and micelles from polysorbate 80 and soyabean oil for formulation iii), in the intestine might induce a decrease of the drug solubilization with the bile salts.

Recently the effect of an organized lipid matrix emulsion containing lyso-phosphatidylcholine, monoglycerides, and fatty acids (ratio 1:4:2) was given along with a traditional capsule formulation of retinyl palmitate (Lepage et al 2002). The lipid matrix emulsion yields a single melting point (64 °C) which is much lower than the melting point of its individual components. It produces an eutectic matrix due to the interaction of monoglycerides with the lyso-phosphatidylcholine. The absorption in cystic fibrosis adolescent patients, who have an impaired pancreatic function, was compared with that upon administration of the same dose of retinyl palmitate given along with a conventional isocaloric TG based nutritional supplement. It was concluded that the AUC (over baseline) for the organized lipid matrix was 10-fold higher compared with the TG based formula. The organized lipid matrix formula needed no hydrolysis before absorption, and could lead to a less variable absorption. This organized lipid matrix emulsion has also been tested in human subjects with the compound 4-Hydroxylphenylretinamide (4-HPR) a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia. The bioavailability of a 4-HPR oral capsule formulation resulted in poor patient compliance at higher doses (due to the large number of capsules) in phase I trials of high-dose oral 4-HPR and high inter-patient variations. Using a lipid matrix emulsion it was possible to reduce the dose to 20% of the traditional formulation and still obtain equivalent peak plasma concentrations (Avanti® Polar Lipids, Inc. 2006).

Dry emulsions consisting of redispersed freeze-dried drug-milk formulations have been evaluated using reconstitution in vitro to obtain an o/w emulsion before administration for dicumarol (an anticoagulant) (Macheras and Reppas 1986a) and nitrofurantoin (a bactericiodal) (Macheras and Reppas 1986b) respectively. Capsules containing the pure drugs were used as controls in both cases. Analysis of urine data revealed superiority of the nitrofurantoin-milk formulations regenerated with 200 and 400 ml of milk over the corresponding capsule formulations in the rates and extents of nitrofurantoin excretion. Determination of the plasma dicumarol levels indicated superiority of the dicumarol-milk formulation. Statistically significant differences were found between area under the curve, maximum plasma concentration, and apparent elimination rates.

The introduction of the organized lipid matrix emulsion which can be used with further hydrolysis is an interesting approach. The main advantage of this formulation is that no hydrolysis is needed which can result in less variations in absorption. However it is rather difficult to draw conclusions for the applicability of this formulation since the data from the literature are quite limited at the moment. Furthermore
the potential of the drug-milk freeze-dried formulations for the enhancement of the bioavailability of sparingly water soluble drugs are not yet elucidated.

Self emulsifying drug delivery systems

Self (micro) emulsifying drug delivery systems have attracted a lot of attention lately. Their thermotropic stability and the high drug loading efficiency make them a promising system for poorly water soluble drugs giving particles with small size.

Julianto and colleagues (2000) demonstrated that a SEDDS increased the bioavailability of α-tocopherol approximately 210%–410% compared with a commercially available soybean oil solution. The antioxidant α-tocopherol, a lipid soluble vitamin (vitamin E), is a poorly aqueous soluble compound. Traditionally α-tocopherol has been formulated as a capsule containing a simple oil solution. Both the SEDDS and the commercial α-tocopherol formulation contained 400 mg α-tocopherol. The SEDDS contained Tween 80: Span 80: Vitamin E (4:2:4) and the commercial formulation contained of α-tocopherol dissolved in soybean oil. Both the AUC_{0–24} and C_{max} values of the SEDDS were markedly higher than those of the oil solution, while the T_{max} was shorter, indicating a higher rate and extent of absorption. No physicochemical characterization was performed and it was not stated if the lipid amount were equal between the formulations.

In a recent study the bioavailabilities of three different lipid formulations of tocotrienols (Yap et al 2004) were investigated. Two self-emulsifying systems SEDDS, containing varying amounts of soybean oil, Tween 80 and Labrasol (C8/C10 polyglycolyzed glycerides from coconut oil) was analysed according to their self-emulsifying properties, droplet sizes and extent of lipolysis. The droplet size was 1.5 and 10.6 μm respectively. Formulations containing 200 mg mixed tocotrienols administered in healthy adults as SEDDS or simple soybean oil solution stated that the SEDDS had markedly higher plasma levels and a faster onset of absorption compared with the oily solution. The droplet size difference between the two SEDDS did not affect the bioavailabilities. However, the total dosed lipid amounts between the three explored formulations ranged from 31.3–351.3 mg soybean oil thus making the interpretation of the bioavailabilities more complex.

The potent anti-HIV drug saquinavir has been enrolled in studies with human subjects in lipid based formulations. It has been formulated into SEDDS. The drug is available in the market in both hard gelatine capsule (Invirase), containing saquinavir with lactose microcrystalline cellulose, povidone K30, sodium starch glycolate, tcalc and magnesium stearate and soft gelatin capsules (Fortovase), containing saquinavir in solutions in medium chain mono- and -diglycerides, povidone and dl-alpha tocopherol. In a recent study (Roche Laboratories, Inc 2004), a significant improvement to the bioavailability up to 331% of soft gelatine capsules compared with hard gelatine capsules. Ritonavir (Norvir) is available as in soft gelatin capsules with oleic acid, ethanol, poloxyl 35 castor oil titanium dioxide, iron oxide and butylated hydroxytoluene (FDA 2006).

When healthy subjects were administered with saquinavir/ritonavir 1600 mg/100 mg, and no difference in AUC_{0–24} values between hard and soft gelatine capsules was observed, respectively (Cardiello et al 2003). The pharmacokinetics and the safety of a boosted saquinavir/ritonavir combination either with hard gelatin capsules or soft gelatin capsules was evaluated (Kurowski et al 2003). Comparable plasma exposures with saquinavir achieved when saquinavir boosted with ritonavir, accompanied by an improvement in gastrointestinal system disorders.

The turning point for development of the oral lipid and surfactant based formulations of poorly soluble drugs was the introduction to the market of cyclosporine A (CsA) in a lipid based formulation. CsA is an immunosuppressant used in chronic treatment of organ transplant receivers to suppress graft rejection and in the treatment of severe rheumatic arthritis and severe psoriasis.

The Sandimmune and Sandimmune Neoral formulations of CsA are perhaps the best known examples of a marketed lipid and surfactant based systems and the pharmacokinetic has been studied and reviewed extensively (Holt et al 1994; Ritschel 1996). Cyclosporine was introduced in 1981 in Europe in a self-emulsifying formulation (Sandimmune) containing Labrafil M 1944 CS (polyoxyethylated oleic glycerides), olive oil and ethanol (Klyashchitsky and Owen 1998). This formulation disperses, when diluted with water, into a polydisperse oil-in-water macroemulsion. In 1994 a new self-microemulsifying formulation (Sandimmune Neoral, referred to as Neoral in the following) was introduced, which emulsifies spontaneously into a microemulsion with a particle size smaller than 100 nm. This formulation contains Cremophor RH40 (polyoxyyl hydrogenated castor oil), corn oil glycerides, propylene glycol and ethanol (Klyashchitsky and Owen 1998).

Drew and colleagues investigated the absorption of CsA (150 mg) from three experimental formulations using
Sandimmune as reference in fasting healthy volunteers. Two of the experimental formulations were microemulsions with respectively fast and slow in vitro release. The microemulsions were formulated using polyethylene glycol, hydrogenated castor oil, and medium chain triglycerides and low molecular weight glycols. The last experimental formulation was a solid micellar solution with fast in vitro release composed of sucrose monolaurate and propylene glycol. The fast releasing microemulsion and the fast releasing solid micellar solution exhibited significant higher C\text{max} and bioavailability (141% and 139% of Sandimmune, respectively). The slow releasing microemulsion was equivalent to Sandimmune with respect to C\text{max} and bioavailability. The T\text{max} of the tested formulations were in the same range (Drewe et al 1992).

Mueller and colleagues (1994a) investigated the dose linearity of CsA from Sandimmune and Neoral in healthy volunteers who had been fasting 12 h prior to and 4 h after administration finding that Neoral exhibited linear dose AUC relationship in the range of 200 to 800 mg in contrast to Sandimmune. The relative bioavailability of Neoral compared with Sandimmune was found to be in the range of 174–239% but dependent on the actual dose, with the highest dose resulting in the largest difference in bioavailability. It must be noted that the bioavailability for Neoral and a number of the generic products of CsA exhibited marked pharmacokinetic variations in different human subpopulations even though they had been found bioequivalent. This discussion is however beyond the scope of this article and has been reviewed recently elsewhere (Dunn et al 2001; Pollard et al 2001). Studies in fasted healthy volunteers comparing Sandimmune (300 mg CsA) and Neoral (180 mg CsA) it was found that Neoral exhibit shorter T\text{max} and higher C\text{max} and AUC (Mueller et al 1994a, 1994b; Kovarik et al 1994).

Recently an experimental CsA self-emulsifying galactolipid formulation has been compared with Neoral in fasting healthy volunteers (Odeberg et al 2003). The self-emulsifying galactolipid formulation forms an emulsion with mean particle size of 16–20 \mu m. The galactolipid formulations exhibited identical T\text{lag} and T\text{max} but slightly lower C\text{max} (94%) and AUC (84%) when compared with Neoral (Odeberg et al 2003). In another study the bioavailability of a non-SMEDDDS, which is semisolid opaque oily suspension that in aqueous solution forms particles with a mean diameter 200 nm, and a SMEDDDS formulation of cyclosporine were tested (Postolache et al 2002). The results showed that the non-SMEDDDS formulation was not bioequivalent with the SMEDDDS formulation due to a statistical significant lower absorption rate. The authors claimed that with this study it has been demonstrated that in vivo the non-SMEDDDS capsules are not totally interchangeable compared with the SMEDDDS capsules. In a different approach cyclosporine lipid nanoparticles (lipospheres) were developed (Bekerman et al 2004) and the effect of composition and particle size investigated. These lipospheres consisted of phospholipids, Span 80, Tween 80, Tricaprin, and Cremophor RH 40. Cyclosporin dispersions systems resulting in particle size of 25 up to 400 nm prepared. Oral bioavailability indicated a correlation between the AUC and C\text{max} and the particle size of the dispersion showing the highest values for particles with 25 nm diameter. The clinical formulation of Neoral used as a reference. This study demonstrated a correlation between the particle size and the oral bioavailability of cyclosporine formulations. Furthermore the composition and possibly the surface properties of the lipid nanoparticles (lipospheres) could affect the oral bioavailability of cyclosporine.

The above clearly demonstrate that SEDDDS can be a promising formulation approach for poorly water soluble drugs. The efficiency of these systems is rather case-specific depending on the composition of the formulation used each time.

**Surfactant-based solutions**

Cremophor is commonly used excipient in lipid-based formulations (Strickley 2004). Cremophor EL may inhibit PGP (p-glycoprotein), a relevant efflux pump which is expressed in high amount in gut, biliary tract and the blood brain barrier, and enzymes like CYP3A which may contribute to first pass metabolism.

Cremophor EL, is used as a vehicle for the solubilization of a wide variety of hydrophobic drugs, including anesthetics, photosensitizers, sedatives, immunosuppressive agents and anticancer drugs including the anticancer agent paclitaxel (Taxol).

The role of the surfactants Cremophor EL and Tween 80 and the absorption rate of paclitaxel was investigated by Malingre and colleagues (2001). In this study the 2 formulations were tested; 6 mg/ml paclitaxel in Cremophor EL: ethanol 1:1 v/v or in polysorbate 80: ethanol 1:1 v/v. The Polysorbate 80 formulation performed better than Cremophor EL formulation, both with regard to AUC and C\text{max}. The results demonstrated that the presence of Cremophor EL limited the oral absorption of paclitaxel and they highlight the need of designing a better drug formulation in order to increase the oral absorption of paclitaxel.
In another approach (Martin-Facklam et al 2002) saquinavir in hard gelatine capsules (Invirase) was administered with increasing doses of Cremophor EL (up to 5 g) in volunteers by mixing the content of Invirase capsules with the appropriate amount of Cremophor EL and dispersing it into hard gelatine capsules. When 5 g Cremophor EL were administered the C\text{max} of saquinavir increased from 8.8 ± 8.5 nmol/l for control (Invirase capsule) to 112.7 ± 74.4 nmol/l respectively. Increasing levels of Cremophor increased the AUC of saquinavir. It is suggested that Cremophor EL acts as a modulator of the absorption process by inhibiting intestinal PGP.

Barker and colleagues (2003) explored a 50% (w/w) solid dispersion of α-tocopherol in Gelucire 44/14 that comprises a mixture of pegylated fatty acid esters and glycerides. Compared with a commercial oil solution of α-tocopherol a two-fold increase in absorption was found after administration of the solid dispersion of α-tocopherol. The AUC\text{\textsubscript{\infty}} and C\text{max} were considerably higher after administration of the solid dispersion compared with the commercial product. Additionally, the lag phase prior to absorption of α-tocopherol from the solid dispersion was markedly shorter than for the commercial oil solution. Interestingly, the absorption profile appeared to be bi-phasic with a second peak after 10 hours, presumably due to a 10 h post-dose meal. The fact that this second phase of the absorption of α-tocopherol occurred after the volunteers were fed (at 10 h post-dose) according to the authors was possible due to the mobilisation of the lipid-absorbing pathway in response to food.

The data with surfactant-based formulations are too limited to draw safe conclusions on and more studies are needed to clarify their role since many possible mechanisms are in play. New excipients like Gelucire and Labrasol can solubilize many drugs and will possibly be used more frequently in the future. They are similar to the Labrafil and they consist of mixtures of mono-, di- and triglycerides and mono- and di-fatty acid esters of polyethyleneglycol with fatty acid compositions. However how these excipients perform in vivo is a crucial parameter for their success.

Food effect

The food-drug interactions may depend on several factors such as the physical and chemical characteristics of the drug, the size and the composition of the meal or the time of drug intake in relation with the meal (Singh 1999).

A claimed advantage of certain lipid-based formulations is that the food effect on poorly soluble drug can be diminished as it has been demonstrated by Mueller and colleagues (1994b).

The impact of a high-fat meal on the pharmacokinetics of CsA from Sandimmune and Neoral has been investigated in healthy volunteers. In a study comparing Sandimmune (300 mg CsA) and Neoral (180 mg CsA) it was found that food influences the pharmacokinetics of CsA from Sandimmune more profoundly than from Neoral. A significant prolongation of T\text{lag} and T\text{max} and an increase in AUC was found for Sandimmune (Mueller et al 1994b). For the Neoral formulation the T\text{lag} and T\text{max} were only slightly and insignificantly increased whereas both C\text{max} and AUC were reduced though significantly (Mueller et al 1994b). In the fasted state the relative bioavailability of CsA from Neoral was slightly higher (114% of Sandimmune) compared with Sandimmune but when administered after a high-fat meal the bioavailability from Neoral was considerable lower (71.4% of Sandimmune) than from Sandimmune (Mueller et al 1994b). In another study in which healthy volunteers was administered 7.5 mg/kg CsA after a high-fat breakfast it was found that the bioavailability of Neoral was 109.3% compared with Sandimmune (Gonzalez-Llaven et al 1999). The difference in relative bioavailability of Neoral compared with Sandimmune in the two studies performed by Mueller and colleagues (1994b) and Gonzalez-Llaven and colleagues (1999), could be explained by the difference in dose. When correcting the relative bioavailability for the difference in dose under the assumption of linear pharmacokinetics in the study by Mueller et al the bioavailability of Neoral is 190% and 119% of Sandimmune in fasted and fed state respectively. This emphasizes the importance of administering equal doses when investigating the food effect on different formulations.

The concentration versus time profile for Sandimmune show, for a considerable number of individuals, two peaks in both fasting individuals (Mueller et al 1994a, 1994b; Kovarik et al 1994) and individuals fed a high-fat breakfast (Mueller et al 1994b). This could suggest that the absorption of CsA from the Sandimmune formulation was limited by gastric emptying or the food consumed 4 h after administration.

A lipid emulsion of danazol was dosed to human subjects and the pharmacokinetics was studied (Charman et al 1994a). A commercial formulation as a powder (hard gelatin capsule) and a lipid emulsion formulation of danazol were tested in both fed and fasted states. The commercial formulation contained 100 mg danazol in a capsule and the lipid formulation contained 3.43 mg of danazol per gram of emulsion dose. The lipid phase of the emulsion consisted of glycerol.
monoleate. In the fasted state the AUC for the lipid based formulation was 5 time higher than the powder formulation. However, no significant difference observed between the two formulations in the fed state.

Unfortunately the data from the literature are rather limited can not give a clear answer to the question, whether the lipid formulations are able to overcome food effect.

**Summary**

Oral route is the preferred for the administration of drugs. Since a lot of potential drug candidates are poorly soluble in water, resulting in poor and variable oral bioavailability, many approaches have been employed in order to produce formulations with a high and reproducible bioavailability. Development of lipid based formulations has recently attracted a lot of attention. Lipid based systems are defined as emulsions, microemulsion, SEDDS, micellar suspensions, and oil solutions. However, most proof of concept studies have been carried out using animal models. As is obvious from the above the number of clinical studies evaluating the benefits of lipid based formulations is rather limited. The clinical data described in this article indicates that the studies could be separated in two different time-periods, based on the design and the performed clinical trials. In the first period which covers the period from the early sixties up to late eighties the lipid formulations mainly consist of an oil solution of the drug or an oil macroemulsion. The physicochemical characterization at this stage is rather poor or nonexisting. But in almost all the cases the lipid formulations or emulsions performed better than the tablets.

The second period for lipid based formulations starts in the first half of the 1990s, with the entrance in the market of a SMEDDS (Neoral) of cyclosporine which produces a finely dispersed microemulsion when diluted in an aqueous phase emphasized the impact of the physicochemical properties of the lipid vehicles compared with formulations tested before.

A number of studies have reported higher bioavailability with decreased particle size when comparing self-emulsifying formulations (Drewe et al 1992; Kovarik et al 1994; Gao et al 1998; Odeberg et al 2003). However the formulations investigated in these studies made use of either different surfactant and lipid phases or different ratios between the surfactant and the lipid phase. This fact impedes a conclusion with regard to the optimal composition of SMEDDS, since it is well described that formulations with matching particle size but different lipid phases can exhibit different bioavailability values (Khoo et al 1998).

The choice of surfactants and lipids is a crucial factor for the in vivo fate of the formulation. The lipids play a significant role since they can increase the drug solubility in lumen, can change the physical (Aungst 2000) and the biochemical barrier function (Benet 2001) of the GI tract and they can stimulate the lymphatic transport (Porter and Charman 1997).

Furthermore the food-drug interactions are important to drug absorption. Concomitant food intake has been demonstrated to lead to an increase in drug bioavailability. However when a microemulsion was administered a reduced effect of food on bioavailability was noticed (Mueller et al 1994b).

The fact that only four drug products, Sandimmune® and Sandimmune Neoral® (cyclosporin A), Norvir® (ritonavir), and Fortovase® (saquinavir) are on the market in combination with the hydrophobic nature of many drug candidates implies that the studies with lipid based formulations have to be more intensive and more systematic.

Finally the stability of these formulations is a parameter that has been rather underestimated since there is lack of studies and data on this issue. However the success of the each formulation in perspectives of being released in the market as a commercial product is highly dependant on its stability in long term, therefore more studies are required.

In conclusion more human bioavailability studies are needed to elucidate the mechanisms of action of these formulations. In parallel the development of new formulations well characterized in terms of their physicochemical properties will offer new insights on their performance in vivo.

**References**

Acosta E, Kurlat DH, Bisceglia M, et al. 1996. Induced electric birefringence and viscosity studies in microemulsions. *Colloids Surfaces A: Physicochem Eng Aspects*, 106:11–21.

Angelucci L, Petrangeli B, Celletti P, et al. 1976. Bioavailability of flufenamic acid in hard and soft gelatin capsules. *J Pharm Sci*, 65:455–6.

Armstrong NA, James KC. 1980. Drug release from lipid based dosage forms. II. *Int J Pharm*, 6:195–204.

Avanti® Polar Lipids, Ltd. 2006 High-dose fenretinide delivery with novel Lym-X-Sorb® organized lipid complex [online]. Accessed on December 1st, 2006. http://www.avantilipids.com/LXS-DD.asp.

Aungst BJ. 2000. Intestinal permeation enhancers. *J Pharm Sci*, 89:429–42.

Bakatselou V, Oppenheim RC, Dressman JB. 1991. Solubilization and wetting effects of bile salts on the dissolution of steroids. *Pharm Res*, 8:1461–9.

Barker SA, Yap SP, Yuen KH, et al. 2003. An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14. *J Contr Rel*, 91:477–88.

Bates TR, Sequeira JA. 1975. Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. *J Pharm Sci*, 64:793–7.

Bates TR, Pieniaszek HJ Jr, Sequeira JA, et al. 1977. Gastrointestinal absorption of griseofulvin from corn oil-in-water emulsions: effect of amount of corn oil ingested in man. *Arch Dermatol*, 113:302–6.
Bekerman T, Golenser J, Domb A. 2004. Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci, 93:1264–70.

Benet L. 2001. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev, 50:S3–S11.

Bergenholtz J, Romagnoli AA, Wagner NJ. 1995. Viscosity, microstructure and interparticle potential of AOT/H2O/decane inverse microemulsions. Langmuir, 11:1559–70.

Bruni G, Galletti F. 1970. Steroidal ethers: urinary excretion of pregnane- diols in man after ingestion of quinagesterone in fasting or non-fasting conditions. Steroidology, 1:89–93.

Cardiello PG, Monhaphol T, Mahanontharit A, et al. 2003. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J AIDS, 32:375–9.

Charman WN, Rogge MC, Boddy AW, et al. 1993. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol, 33:381–6.

Constantinides PP, Scalart JP. 1997. Formulation and physical characterization of water-in-oil microemulsions containing long versus medium chain length glycerides. Int J Pharm, 158:57–68.

Cornaire G, Woodley J, Hermann P, et al. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm, 278:119–31.

de Smidt PC, Campanero MA, Troconiz IF. 2004. Intestinal absorption of pencolomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Int J Pharm, 270:109–18.

Drewe J, Meier R, Vondracher J, et al. 1992. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol, 34:60–4.

Dunn CJ, Wagstaff AJ, Perry CM, et al. 2001. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs, 61:1957–2016.

e1 Tayar N, Mark AE, Vallat P, et al. 1993. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem, 36:3757–64.

[FDA] Food and Drug Administration. 2006. Ritonavir prescribing information [online]. Accessed on December 1st, 2006. URL: http://www.fda.gov/cder/foi/label/2003/20659s030,20945s013_novir_tbl.pdf.

Fischler M, Frisch EP, Ortengren B. 1973. Plasma concentrations after oral administration of different pharmaceutical preparations of clofazimine. Acta Pharm Suec, 10:483–92.

Gao ZG, Choi HG, Shin HJ, et al. 1998. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. J Pharm Sci, 87:161–9.

Gershani T, Benita S. 2000. Self-dispersing lipid formulations for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 50:179–88.

Gonzalez-Llaven J, Palma-Aguirre JA, Garcia-Arreola R, et al. 1999. Comparative bioavailability evaluation of two cyclosporine oral formulations in healthy Mexican volunteers. Arch Med Res, 30:315–19.

Gursoy RN, Benita S. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 58:173–82.

Hargrove JT, Maxson WS, Wentz AC. 1989. Absorption of oral proges- terone is influenced by vehicle and particle size. Am J Obstet Gynecol, 161:498–51.

Holmberg I, Aknes L, Berlin T, et al. 1990. Absorption of a pharmacological dose of vitamin D3 from two different lipid vehicles in man: comparison of peanut oil and a medium chain triglyceride. Biopharm Drug Dispos, 11:807–15.

Holt DW, Mueller EA, Kovarik JM, et al. 1994. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc, 26:2935–9.

Hugger ED, Novak BL, Burton PS, et al. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci, 91:1991–2002.

Humberstone AJ, Charman WN. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103–28.

Hunt JN, Knox MT. 1968. A relation between the chain length of fatty acids and the slowing of gastric emptying. J Physiol, 194:527–36.

Julianto T, Yuen KH, Noor AM. 2000. Improved bioavailability of vitamin E with a self- emulsifying formulation. Int J Pharm, 200:53–7.

Karpf DM, Holm R, Kristensen HG, et al. 2004. Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats. Pharm Res, 8:1413–18.

Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. 1998. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Inter J Pharm, 167:155–64.

Khosravi M, Kao YH, Mrsny RJ, et al. 2002. Analysis methods of polysorbate 20: A new method to assess the stability of polysorbate 20 and established methods that may overlook degraded polysorbate 20. Pharm Res, 5:634–9.

Klyachitsky BA, Owen AJ. 1998. Drug delivery systems for cyclosporine: achievements and complications. J Drug Target, 5:443–458.

Kovarik JM, Mueller EA, Johnston A, et al. 1993. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. J Pharm Pharmacol, 45:13–17.

Kovarik JM, Mueller EA, van Bree JB, et al. 1994. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci, 83:444–6.

Kurowski M, Sternfield T, Sawyer A, et al. 2003. Pharmacokinetic and tolerability profile of twice daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine, 4:94–100.

Ladas SD, Isaacs PE, Murphy GM, et al. 1994. Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut, 4:405–11.

Lepage G, Yesair DW, Ronco N, et al. 2002. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr, 141:178–85.

Larsen A, Jannin V, Mullertz A. 2006. Pharmaceutical surfaces in biorelevant media: impact on lipolysis and solubility of a poorly soluble model compound: danazol. Proceedings 5th World Meeting in Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 27–30, Geneva, Switzerland.

Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89–121.

Macheras PE, Reppas CI. 1986a. Studies on drug-milk freeze-dried formulations. I: Bioavailability of sulfamethizole and dicumarol formulations. J Pharm Sci, 75:692–6.

Macheras PE, Reppas CI. 1986b. Studies on freeze-dried drug-milk formulations. II: Effect of regenerated fluid volume on nitrofurantoin bioavailability. J Pharm Sci, 75:1145–50.

Martin-Facklam M, Burhenne J, Ding R, et al. 2002. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol, 53:576–81.

Malingre MM, Schellens JH, Van Tellingen O, et al. 2001. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer, 85:1472–7.

Mueller EA, Kovarik JM, van Bree JB, et al. 1994a. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res, 11:301–4.

Mueller EA, Kovarik JM, van Bree JB, et al. 1994b. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a cross-over comparison with the market formulation. Pharm Res, 11:151–5.

Nielsen FS, Gibault E, Ljusberg-Wahrer H, et al. 2007. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. J Pharm Sci, 96:876–92.

Odeberg JM, Kaufmann P, Kroon KG, et al. 2003. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. J Eur Pharm Sci, 20:375–82.
Pollard S, Nashan B, Johnston A, et al. 2003. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. *Clin Ther*, 25:1654–69.

Porter CJ, Charman WN. 1997. Uptake of drugs into the intestinal lymphatics after oral administration. *Adv Drug Deliv Rev*, 25:71–89.

Porter CJ, Charman WN. 2001. In vitro assessment of oral lipid based formulations. *Adv Drug Deliv Rev*, 50:S127–S147.

Porter CJ, Kaukonen AM, Boyd BJ, et al. 2004. Susceptibility to lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation. *Pharm Res*, 8:1405–12.

Pouton CW. 2006. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *Eur J Pharm Sci*, 29:278–87.

Postolache P, Petrescu O, Dorneanu V, et al. 2002. Cyclosporine bioavailability of two physically different oral formulations. *Eur Rev Med Pharmacol Sci*, 6:127–31.

Pouton CW. 1997. Formulation of self-emulsifying drug delivery systems. *Adv Drug Deliv Rev*, 25:47–58.

Pouton CW. 2000. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. *Eur J Pharm Sci*, 11:S93–S98.

Rege BD, Kao JP, Polli JE. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. *Eur J Pharm Sci*, 16:237–46.

Regev O, Ezrahi S, Aserin A, et al. 1996. A study of the microstructure of a four-component nonionic microemulsion by cryo-TEM, NMR, SAXS and SANS. *Langmuir* 12:668–74.

Ritschel WA. 1996. Microemulsions for improved peptide absorption from the gastrointestinal tract. *Methods Find Exp Clin Pharmac*, 13:205–20.

Roche Laboratories, Inc. 2004a. Fortovase® prescribing information [online]. Accessed on December 1, 2006. URL: http://www.rocheusa.com/products/fortovase/pi.pdf.

Rolan PE, Mercer AJ, Weatherley BC, et al. 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. *Br J Clin Pharmacol*, 37:13–20.

Schmidt LE, Dalhoff K. 2002. Food-drug interactions. *Drugs*, 62:1481–502.

Seeballuck F, Ashford MB, O’Driscoll CM. 2003. The effects of pluronics block copolymers and cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. *Pharm Res*, 20:1085–92.

Shono Y, Nishihara H, Matsuda Y, et al. 2004. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. *J Pharm Sci*, 93:877–85.

Singh BN. 1999. Effects of food on clinical pharmacokinetics. *Clin Pharmacokinet*, 37:213–55.

Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. *Pharm Res*, 21:201–30.

Vinson PK, Sheenan JG, Miller WG, et al. 1991. Viewing microemulsions with freeze-fracture transmission electron microscopy. *J Phys Chem*, 95:2546–2550.

Weis M, Mortensen SA, Rassing MR, et al. 1994. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. *Mol Aspects Med*, 15:S273–S280.

Yamahira Y, Noguchi T, Noguchi T, et al. 1979. Absorption of diazepam from a lipid-containing oral dosage form. *Chem Pharm Bull (Tokyo)*, 27:1190–8.

Yap SP, Yuen KH. 2004. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. *Int J Pharm*, 281:67–78.